SIMILAR PATTERNS OF AMINO ACIDS FOR 6DJ2_B_AB1B201_1

List of similar pattern of amino acids derived from ASSAM search

Hit pattern: 3D amino acid arrangements similar to known drug binding site
Query pattern: Residues from known binding site for annotated drug that match the hit pattern

(Click link on the last column to view superposed patterns of amino acids in NGL viewer)
(Note that only 3-12 residue patterns can be used for ASSAM searches)

Filter list by:

	Hit	Macromolecule/ Organism	Pfam	Res.	Interface	HETATM	RMSD	Dali Z-score	Seq. Identity (%)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1bou	4,5-DIOXYGENASE BETA CHAIN (Sphingomonas paucimobilis)	PF02900 (LigB)	5	GLY B 274 ALA B 275 ILE B 8 GLY B 189 VAL B 131	None	0.85A	6dj2B-1bouB: undetectable	6dj2B-1bouB: 14.43
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1fob	BETA-1,4-GALACTANASE (Aspergillus aculeatus)	PF07745 (Glyco_hydro_53)	6	GLY A 40 ALA A 39 ASP A 38 VAL A 324 ILE A 35 ILE A 44	None	1.16A	6dj2B-1fobA: undetectable	6dj2B-1fobA: 11.87
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1hvc	HIV-1 PROTEASE (Human immunodeficiency virus 1)	PF00077 (RVP)	8	ARG A 8 ASP A 25 GLY A 27 ALA A 28 ASP A 30 ILE A 47 ILE A 50 PRO A 81	A79 A 800 (-3.4A) A79 A 800 (-2.7A) A79 A 800 (-3.0A) A79 A 800 (-3.1A) A79 A 800 ( 4.9A) A79 A 800 ( 3.2A) A79 A 800 (-3.8A) A79 A 800 ( 3.9A)	0.80A	6dj2B-1hvcA: 13.7	6dj2B-1hvcA: 41.30
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1hvc	HIV-1 PROTEASE (Human immunodeficiency virus 1)	PF00077 (RVP)	7	ARG A 8 ASP A 25 GLY A 27 ALA A 28 ASP A 30 PRO A 81 VAL A 82	A79 A 800 (-3.6A) A79 A 800 (-2.8A) A79 A 800 (-3.0A) A79 A 800 (-3.2A) A79 A 800 ( 4.7A) A79 A 800 ( 3.4A) A79 A 800 (-4.5A)	0.60A	6dj2B-1hvcA: 13.7	6dj2B-1hvcA: 41.30
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1hvc	HIV-1 PROTEASE (Human immunodeficiency virus 1)	PF00077 (RVP)	10	ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 VAL A 32 ILE A 47 GLY A 49 ILE A 50 PRO A 81	A79 A 800 (-2.8A) A79 A 800 (-3.0A) A79 A 800 (-3.2A) A79 A 800 (-2.7A) A79 A 800 ( 4.7A) A79 A 800 ( 4.3A) A79 A 800 ( 3.4A) A79 A 800 (-3.4A) A79 A 800 ( 4.0A) A79 A 800 ( 3.4A)	0.57A	6dj2B-1hvcA: 13.7	6dj2B-1hvcA: 41.30
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1hvc	HIV-1 PROTEASE (Human immunodeficiency virus 1)	PF00077 (RVP)	11	ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 VAL A 32 ILE A 47 GLY A 49 ILE A 50 PRO A 81 VAL A 82	A79 A 800 (-2.7A) A79 A 800 (-3.0A) A79 A 800 (-3.1A) A79 A 800 (-2.8A) A79 A 800 ( 4.9A) A79 A 800 ( 4.4A) A79 A 800 ( 3.2A) A79 A 800 ( 3.7A) A79 A 800 (-3.8A) A79 A 800 ( 3.9A) A79 A 800 (-4.5A)	0.72A	6dj2B-1hvcA: 13.7	6dj2B-1hvcA: 41.30
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1hvc	HIV-1 PROTEASE (Human immunodeficiency virus 1)	PF00077 (RVP)	10	ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 VAL A 32 ILE A 47 GLY A 49 PRO A 81 VAL A 82	A79 A 800 (-2.8A) A79 A 800 (-3.0A) A79 A 800 (-3.2A) A79 A 800 (-2.7A) A79 A 800 ( 4.7A) A79 A 800 ( 4.3A) A79 A 800 ( 3.4A) A79 A 800 (-3.4A) A79 A 800 ( 3.4A) A79 A 800 (-4.5A)	0.61A	6dj2B-1hvcA: 13.7	6dj2B-1hvcA: 41.30
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1p2f	RESPONSE REGULATOR (Thermotoga maritima)	PF00072 (Response_reg) PF00486 (Trans_reg_C)	5	GLY A 93 ALA A 94 ASP A 95 ILE A 75 ILE A 61	None	0.82A	6dj2B-1p2fA: undetectable	6dj2B-1p2fA: 17.13
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1q8y	SR PROTEIN KINASE (Saccharomyces cerevisiae)	PF00069 (Pkinase)	5	ARG A 287 ASP A 282 GLY A 698 ALA A 697 GLY A 726	None	0.89A	6dj2B-1q8yA: undetectable	6dj2B-1q8yA: 12.76
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1q9p	HIV-1 PROTEASE (Homo sapiens)	PF00077 (RVP)	6	ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 VAL A 32	None	0.41A	6dj2B-1q9pA: 10.1	6dj2B-1q9pA: 98.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1q9p	HIV-1 PROTEASE (Homo sapiens)	PF00077 (RVP)	6	ASP A 25 GLY A 27 ALA A 28 ASP A 30 VAL A 32 PRO A 81	None	0.79A	6dj2B-1q9pA: 10.1	6dj2B-1q9pA: 98.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1siv	SIV PROTEASE (Simian immunodeficiency virus)	PF00077 (RVP)	9	ARG A 8 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 GLY A 49 ILE A 50 PRO A 81	None	0.63A	6dj2B-1sivA: 18.8	6dj2B-1sivA: 49.40
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1vrg	PROPIONYL-COA CARBOXYLASE, BETA SUBUNIT (Thermotoga maritima)	PF01039 (Carboxyl_trans)	6	GLY A 416 ALA A 417 ASP A 418 ILE A 395 ILE A 346 VAL A 360	None	1.10A	6dj2B-1vrgA: undetectable	6dj2B-1vrgA: 11.16
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1x0u	HYPOTHETICAL METHYLMALONYL-COA DECARBOXYLASE ALPHA SUBUNIT (Sulfurisphaera tokodaii)	PF01039 (Carboxyl_trans)	6	GLY A 424 ALA A 425 ASP A 426 ILE A 403 ILE A 354 VAL A 368	None	1.16A	6dj2B-1x0uA: undetectable	6dj2B-1x0uA: 15.08
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1yr2	PROLYL OLIGOPEPTIDASE (Novosphingobium capsulatum)	PF00326 (Peptidase_S9) PF02897 (Peptidase_S9_N)	6	GLY A 539 ALA A 538 ASP A 537 GLY A 529 PRO A 475 VAL A 474	None	1.08A	6dj2B-1yr2A: undetectable	6dj2B-1yr2A: 7.62
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1yw6	SUCCINYLGLUTAMATE DESUCCINYLASE (Escherichia coli)	PF04952 (AstE_AspA)	5	ARG A 250 GLY A 180 ALA A 179 GLY A 242 ILE A 243	None	0.93A	6dj2B-1yw6A: undetectable	6dj2B-1yw6A: 15.44
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2bkl	PROLYL ENDOPEPTIDASE (Myxococcus xanthus)	PF00326 (Peptidase_S9) PF02897 (Peptidase_S9_N)	6	GLY A 497 ALA A 496 ASP A 495 GLY A 487 PRO A 431 VAL A 430	None	1.09A	6dj2B-2bklA: undetectable	6dj2B-2bklA: 10.16
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2eja	UROPORPHYRINOGEN DECARBOXYLASE (Aquifex aeolicus)	PF01208 (URO-D)	5	GLY A 192 ALA A 193 ASP A 194 ILE A 134 ILE A 120	None	0.77A	6dj2B-2ejaA: undetectable	6dj2B-2ejaA: 10.68
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2fmb	EQUINE INFECTIOUS ANEMIA VIRUS PROTEASE (Equine infectious anemia virus)	PF00077 (RVP)	8	ARG A 8 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ILE A 53 PRO A 86 VAL A 87	LP1 A 201 (-3.5A) LP1 A 201 (-2.3A) LP1 A 201 (-3.8A) LP1 A 201 (-3.5A) LP1 A 201 (-3.6A) LP1 A 201 (-4.6A) LP1 A 201 (-3.9A) LP1 A 201 ( 4.9A)	0.64A	6dj2B-2fmbA: 15.0	6dj2B-2fmbA: 28.85
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2fmb	EQUINE INFECTIOUS ANEMIA VIRUS PROTEASE (Equine infectious anemia virus)	PF00077 (RVP)	8	ASP A 25 GLY A 27 ALA A 28 ASP A 29 VAL A 32 ILE A 53 GLY A 55 PRO A 86	LP1 A 201 (-2.3A) LP1 A 201 (-3.8A) LP1 A 201 (-3.5A) LP1 A 201 (-3.6A) None LP1 A 201 (-4.6A) LP1 A 201 (-3.4A) LP1 A 201 (-3.9A)	0.57A	6dj2B-2fmbA: 15.0	6dj2B-2fmbA: 28.85
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2fmb	EQUINE INFECTIOUS ANEMIA VIRUS PROTEASE (Equine infectious anemia virus)	PF00077 (RVP)	8	ASP A 25 GLY A 27 ALA A 28 ASP A 29 VAL A 32 ILE A 53 PRO A 86 VAL A 87	LP1 A 201 (-2.3A) LP1 A 201 (-3.8A) LP1 A 201 (-3.5A) LP1 A 201 (-3.6A) None LP1 A 201 (-4.6A) LP1 A 201 (-3.9A) LP1 A 201 ( 4.9A)	0.58A	6dj2B-2fmbA: 15.0	6dj2B-2fmbA: 28.85
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2fmb	EQUINE INFECTIOUS ANEMIA VIRUS PROTEASE (Equine infectious anemia virus)	PF00077 (RVP)	5	GLY A 27 ALA A 28 ASP A 29 VAL A 32 GLY A 54	LP1 A 201 (-3.8A) LP1 A 201 (-3.5A) LP1 A 201 (-3.6A) None LP1 A 201 (-3.6A)	0.93A	6dj2B-2fmbA: 15.0	6dj2B-2fmbA: 28.85
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2fym	ENOLASE (Escherichia coli)	PF00113 (Enolase_C) PF03952 (Enolase_N)	6	GLY A 174 ALA A 175 VAL A 178 ILE A 182 GLY A 185 ILE A 170	None	1.46A	6dj2B-2fymA: undetectable	6dj2B-2fymA: 11.37
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2isq	CYSTEINE SYNTHASE (Arabidopsis thaliana)	PF00291 (PALP)	5	GLY A 190 ALA A 189 GLY A 183 ILE A 180 PRO A 296	None None PLP A 400 (-3.4A) PLP A 400 (-4.9A) PLP A 400 (-4.0A)	0.79A	6dj2B-2isqA: undetectable	6dj2B-2isqA: 14.24
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2og2	PUTATIVE SIGNAL RECOGNITION PARTICLE RECEPTOR (Arabidopsis thaliana)	PF00448 (SRP54) PF02881 (SRP54_N)	5	GLY A 288 ASP A 70 VAL A 294 GLY A 255 VAL A 302	None	0.97A	6dj2B-2og2A: undetectable	6dj2B-2og2A: 16.01
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2qjg	PUTATIVE ALDOLASE MJ0400 (Methanocaldococcus jannaschii)	PF01791 (DeoC)	5	GLY A 179 ALA A 180 ASP A 181 ILE A 149 VAL A 120	None	0.91A	6dj2B-2qjgA: undetectable	6dj2B-2qjgA: 15.87
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2qma	DIAMINOBUTYRATE-PYRU VATE TRANSAMINASE AND L-2,4-DIAMINOBUTYRAT E DECARBOXYLASE (Vibrio parahaemolyticus)	PF00282 (Pyridoxal_deC)	5	GLY A 728 ALA A 727 ASP A 755 VAL A 774 ILE A 780	None	0.91A	6dj2B-2qmaA: undetectable	6dj2B-2qmaA: 10.54
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2rkf	PROTEASE RETROPEPSIN (Human immunodeficiency virus 1)	PF00077 (RVP)	9	ARG A 8 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 GLY A 49 ILE A 50 PRO A 81	AB1 A 501 ( 4.7A) AB1 A 501 (-2.4A) AB1 A 501 (-3.9A) AB1 A 501 (-3.5A) AB1 A 501 ( 3.3A) AB1 A 501 (-3.8A) AB1 A 501 (-3.5A) AB1 A 501 (-3.8A) AB1 A 501 (-4.2A)	0.47A	6dj2B-2rkfA: 20.4	6dj2B-2rkfA: 80.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2rsp	RSV PROTEASE (Rous sarcoma virus)	PF00077 (RVP)	5	ARG A 10 ASP A 37 GLY A 39 ALA A 40 ASP A 41	None	0.76A	6dj2B-2rspA: 12.7	6dj2B-2rspA: 30.08
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2wk1	NOVP (Actinoalloteichus cyanogriseus)	PF05711 (TylF)	5	GLY A 28 ALA A 27 ILE A 66 GLY A 99 ILE A 102	None None SAH A 301 (-4.1A) None None	0.95A	6dj2B-2wk1A: undetectable	6dj2B-2wk1A: 14.81
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3afo	NADH KINASE POS5 (Saccharomyces cerevisiae)	PF01513 (NAD_kinase)	5	ALA A 48 ASP A 49 ILE A 62 ILE A 195 VAL A 383	None	0.95A	6dj2B-3afoA: undetectable	6dj2B-3afoA: 11.91
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3c24	PUTATIVE OXIDOREDUCTASE (Jannaschia sp. CCS1)	PF03807 (F420_oxidored) PF16896 (PGDH_C)	5	GLY A 164 ALA A 165 ILE A 149 GLY A 120 ILE A 119	None	0.89A	6dj2B-3c24A: undetectable	6dj2B-3c24A: 14.72
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3gt7	SENSOR PROTEIN (Syntrophus aciditrophicus)	PF00072 (Response_reg)	6	ARG A 102 GLY A 107 ALA A 108 ASP A 109 ILE A 59 VAL A 63	None	1.27A	6dj2B-3gt7A: undetectable	6dj2B-3gt7A: 21.05
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3i5g	MYOSIN HEAVY CHAIN ISOFORM A (Doryteuthis pealeii)	PF00063 (Myosin_head) PF00612 (IQ) PF02736 (Myosin_N)	5	GLY A 264 ALA A 265 ASP A 266 GLY A 460 ILE A 459	None	0.88A	6dj2B-3i5gA: undetectable	6dj2B-3i5gA: 6.84
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3igs	N-ACETYLMANNOSAMINE- 6-PHOSPHATE 2-EPIMERASE 2 (Salmonella enterica)	PF04131 (NanE)	5	GLY A 146 ALA A 147 ASP A 148 VAL A 104 ILE A 122	None	0.85A	6dj2B-3igsA: undetectable	6dj2B-3igsA: 16.40
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3ipw	HYDROLASE TATD FAMILY PROTEIN (Entamoeba histolytica)	PF01026 (TatD_DNase)	5	GLY A 112 ASP A 55 GLY A 9 ILE A 8 VAL A 75	None	0.80A	6dj2B-3ipwA: undetectable	6dj2B-3ipwA: 14.75
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3kci	PROBABLE E3 UBIQUITIN-PROTEIN LIGASE HERC2 (Homo sapiens)	PF00415 (RCC1)	5	GLY A4099 ALA A4098 VAL A4042 ILE A3991 GLY A3993	None	0.82A	6dj2B-3kciA: undetectable	6dj2B-3kciA: 12.07
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3kf3	INVERTASE (Schwanniomyces occidentalis)	PF00251 (Glyco_hydro_32N) PF08244 (Glyco_hydro_32C)	5	ASP A 287 GLY A 289 ASP A 291 ILE A 485 PRO A 355	None None None None NAG A5001 ( 4.9A)	0.93A	6dj2B-3kf3A: undetectable	6dj2B-3kf3A: 10.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	PF00077 (RVP)	6	ALA A 28 ASP A 29 ASP A 30 VAL A 32 GLY A 48 PRO A 81	None	1.11A	6dj2B-3mwsA: 19.4	6dj2B-3mwsA: 75.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	PF00077 (RVP)	12	ARG A 8 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 VAL A 32 ILE A 47 GLY A 49 ILE A 50 PRO A 81 VAL A 82	None	0.57A	6dj2B-3mwsA: 19.4	6dj2B-3mwsA: 75.00
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3n0l	SERINE HYDROXYMETHYLTRANSFE RASE (Campylobacter jejuni)	PF00464 (SHMT)	5	GLY A 206 ALA A 205 ILE A 199 PRO A 360 VAL A 284	None	0.95A	6dj2B-3n0lA: undetectable	6dj2B-3n0lA: 12.96
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3njx	RHAMNOGALACTURONASE B (Aspergillus aculeatus)	PF09284 (RhgB_N) PF14683 (CBM-like) PF14686 (fn3_3)	5	GLY A 346 ASP A 349 VAL A 336 GLY A 420 ILE A 419	None CA A 800 (-2.9A) None None None	0.97A	6dj2B-3njxA: undetectable	6dj2B-3njxA: 10.92
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3nns	DNA BINDING RESPONSE REGULATOR B (Thermotoga maritima)	PF00072 (Response_reg)	5	GLY A 93 ALA A 94 ASP A 95 ILE A 75 ILE A 61	None	0.84A	6dj2B-3nnsA: undetectable	6dj2B-3nnsA: 23.36
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3o8l	6-PHOSPHOFRUCTOKINAS E, MUSCLE TYPE (Oryctolagus cuniculus)	PF00365 (PFK)	6	GLY A 224 ALA A 225 ASP A 226 ILE A 260 ILE A 192 VAL A 207	PO4 A 767 ( 4.6A) None None None None None	1.21A	6dj2B-3o8lA: undetectable	6dj2B-3o8lA: 8.52
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3o8o	6-PHOSPHOFRUCTOKINAS E SUBUNIT ALPHA (Saccharomyces cerevisiae)	PF00365 (PFK)	6	GLY A 414 ALA A 415 ASP A 416 ILE A 451 ILE A 382 VAL A 397	None	1.29A	6dj2B-3o8oA: undetectable	6dj2B-3o8oA: 8.03
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3pqs	TRANSFERRIN-BINDING PROTEIN (Actinobacillus pleuropneumoniae)	PF01298 (TbpB_B_D) PF17483 (TbpB_C) PF17484 (TbpB_A)	6	GLY A 463 ALA A 454 ASP A 455 VAL A 429 ILE A 456 GLY A 460	None	1.11A	6dj2B-3pqsA: undetectable	6dj2B-3pqsA: 10.34
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3slz	GAG-PRO-POL POLYPROTEIN (Murine leukemia virus)	PF00077 (RVP)	5	ASP A 32 GLY A 34 ALA A 35 VAL A 39 GLY A 56	3TL A 126 (-2.4A) 3TL A 126 (-3.1A) 3TL A 126 ( 4.0A) None 3TL A 126 (-3.4A)	0.55A	6dj2B-3slzA: 11.1	6dj2B-3slzA: 24.00
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3slz	GAG-PRO-POL POLYPROTEIN (Murine leukemia virus)	PF00077 (RVP)	5	ASP A 32 GLY A 34 ALA A 35 VAL A 39 PRO A 89	3TL A 126 (-2.4A) 3TL A 126 (-3.1A) 3TL A 126 ( 4.0A) None 3TL A 126 (-4.0A)	0.73A	6dj2B-3slzA: 11.1	6dj2B-3slzA: 24.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3t3c	HIV-1 PROTEASE (Human immunodeficiency virus 1)	PF00077 (RVP)	7	ARG A 8 GLY A 27 ASP A 29 VAL A 32 ILE A 47 GLY A 49 ILE A 50	SO4 A 101 (-3.8A) 017 A 201 (-3.4A) 017 A 201 (-3.5A) None None 017 A 201 (-4.0A) 017 A 201 (-3.3A)	0.93A	6dj2B-3t3cA: 18.0	6dj2B-3t3cA: 75.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3t3c	HIV-1 PROTEASE (Human immunodeficiency virus 1)	PF00077 (RVP)	10	ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 VAL A 32 ILE A 47 GLY A 49 ILE A 50 PRO A 81	017 A 201 (-2.6A) 017 A 201 (-3.4A) 017 A 201 (-3.5A) 017 A 201 (-3.5A) 017 A 201 (-4.2A) None None 017 A 201 (-4.0A) 017 A 201 (-3.3A) None	0.96A	6dj2B-3t3cA: 18.0	6dj2B-3t3cA: 75.00
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3t44	INDOLE-3-GLYCEROL PHOSPHATE SYNTHASE (Mycobacterium tuberculosis)	PF00218 (IGPS)	5	GLY A 235 ALA A 236 ASP A 237 ILE A 217 ILE A 206	None	0.71A	6dj2B-3t44A: undetectable	6dj2B-3t44A: 15.12
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3ttp	HIV-1 PROTEASE (Human immunodeficiency virus 1)	PF00077 (RVP)	9	ARG A 8 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 GLY A 49 ILE A 50 PRO A 81	017 A 201 ( 4.8A) 017 A 201 (-2.6A) 017 A 201 (-3.6A) 017 A 201 (-3.4A) 017 A 201 (-3.3A) 017 A 201 (-4.6A) 017 A 201 (-3.0A) 017 A 201 (-3.3A) 017 A 201 (-4.1A)	0.44A	6dj2B-3ttpA: 19.3	6dj2B-3ttpA: 75.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3u7s	POL POLYPROTEIN (Human immunodeficiency virus 1)	PF00077 (RVP)	6	ARG A 8 ASP A 25 ALA A 28 ASP A 30 GLY A 49 ILE A 50	None 017 A 202 ( 2.5A) 017 A 201 (-3.4A) 017 A 201 ( 4.0A) 017 A 202 (-2.9A) 017 A 201 ( 3.5A)	1.43A	6dj2B-3u7sA: 19.6	6dj2B-3u7sA: 76.25
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3u7s	POL POLYPROTEIN (Human immunodeficiency virus 1)	PF00077 (RVP)	10	ARG A 8 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 ILE A 47 GLY A 49 ILE A 50 PRO A 81	None 017 A 202 ( 2.5A) 017 A 201 ( 3.5A) 017 A 201 (-3.4A) 017 A 201 (-3.2A) 017 A 201 ( 4.0A) 017 A 202 (-3.6A) 017 A 202 (-2.9A) 017 A 201 ( 3.5A) 017 A 202 (-4.0A)	0.70A	6dj2B-3u7sA: 19.6	6dj2B-3u7sA: 76.25
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3uhl	PROTEASE (Human immunodeficiency virus 1)	PF00077 (RVP)	6	ASP A 25 GLY A 27 ALA A 28 ASP A 29 PRO A 81 VAL A 82	None	0.65A	6dj2B-3uhlA: 15.8	6dj2B-3uhlA: 80.00
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4b2o	YMDB PHOSPHODIESTERASE (Bacillus subtilis)	PF13277 (YmdB)	5	GLY A 59 ALA A 60 ASP A 61 ILE A 35 VAL A 9	None	0.76A	6dj2B-4b2oA: undetectable	6dj2B-4b2oA: 14.63
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4dzh	AMIDOHYDROLASE (Xanthomonas campestris)	PF01979 (Amidohydro_1)	5	ALA A 355 ILE A 25 GLY A 370 ILE A 369 VAL A 381	None	0.92A	6dj2B-4dzhA: undetectable	6dj2B-4dzhA: 10.78
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4ezd	UREA TRANSPORTER 1 (Bos taurus)	PF03253 (UT)	5	GLY A 333 VAL A 64 ILE A 228 GLY A 230 ILE A 130	SEY A 401 (-3.6A) None None SEY A 401 ( 4.0A) None	0.95A	6dj2B-4ezdA: undetectable	6dj2B-4ezdA: 12.26
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4ict	CYTOCHROME P450 121 (Mycobacterium tuberculosis)	PF00067 (p450)	5	ARG A 184 GLY A 191 ALA A 190 ASP A 220 GLY A 227	None	0.77A	6dj2B-4ictA: undetectable	6dj2B-4ictA: 10.96
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4ilk	STARVATION SENSING PROTEIN RSPB (Escherichia coli)	PF00107 (ADH_zinc_N) PF08240 (ADH_N)	5	GLY A 206 ALA A 207 ASP A 208 ILE A 190 ILE A 176	None	0.78A	6dj2B-4ilkA: undetectable	6dj2B-4ilkA: 11.44
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4j5u	SERINE HYDROXYMETHYLTRANSFE RASE (Rickettsia rickettsii)	PF00464 (SHMT)	5	ALA A 173 ASP A 201 VAL A 224 ILE A 202 PRO A 219	None LLP A 230 ( 2.9A) None None None	0.92A	6dj2B-4j5uA: undetectable	6dj2B-4j5uA: 11.81
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4jga	3-OXOACYL-[ACYL-CARR IER-PROTEIN] SYNTHASE 2 (Rickettsia rickettsii)	PF00109 (ketoacyl-synt) PF02801 (Ketoacyl-synt_C)	5	GLY A 276 ALA A 301 ASP A 304 ILE A 273 ILE A 184	None	0.94A	6dj2B-4jgaA: undetectable	6dj2B-4jgaA: 10.09
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4kpu	ELECTRON TRANSFER FLAVOPROTEIN ALPHA/BETA-SUBUNIT (Acidaminococcus fermentans)	PF01012 (ETF)	5	GLY B 77 ALA B 78 ASP B 79 VAL B 5 ILE B 3	None	0.95A	6dj2B-4kpuB: undetectable	6dj2B-4kpuB: 16.03
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4m0d	N-ACETYLMURAMIC ACID 6-PHOSPHATE ETHERASE (Haemophilus influenzae)	PF01380 (SIS)	6	GLY A 107 ALA A 106 ASP A 129 VAL A 153 ILE A 74 GLY A 80	None	1.38A	6dj2B-4m0dA: undetectable	6dj2B-4m0dA: 19.70
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4m98	PILIN GLYCOSYLATION PROTEIN (Neisseria gonorrhoeae)	PF00132 (Hexapep)	5	GLY A 302 VAL A 295 ILE A 289 ILE A 324 VAL A 331	None	0.96A	6dj2B-4m98A: undetectable	6dj2B-4m98A: 19.43
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4njv	PROTEASE (Human immunodeficiency virus 1)	PF00077 (RVP)	5	ALA A 28 ASP A 29 ASP A 30 VAL A 32 GLY A 48	RIT A 500 (-3.6A) RIT A 500 (-3.2A) RIT A 500 (-4.8A) None RIT A 500 (-4.8A)	0.83A	6dj2B-4njvA: 20.0	6dj2B-4njvA: 85.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4njv	PROTEASE (Human immunodeficiency virus 1)	PF00077 (RVP)	10	ARG A 8 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 VAL A 32 GLY A 49 ILE A 50 PRO A 81	RIT A 500 (-3.2A) RIT A 500 (-2.4A) RIT A 500 (-3.9A) RIT A 500 (-3.6A) RIT A 500 (-3.2A) RIT A 500 (-4.8A) None RIT A 500 (-3.4A) RIT A 500 (-4.3A) RIT A 500 (-3.9A)	0.57A	6dj2B-4njvA: 20.0	6dj2B-4njvA: 85.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4njv	PROTEASE (Human immunodeficiency virus 1)	PF00077 (RVP)	10	ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 VAL A 32 ILE A 47 GLY A 49 ILE A 50 PRO A 81	RIT A 500 (-2.4A) RIT A 500 (-3.9A) RIT A 500 (-3.6A) RIT A 500 (-3.2A) RIT A 500 (-4.8A) None RIT A 500 ( 4.5A) RIT A 500 (-3.4A) RIT A 500 (-4.3A) RIT A 500 (-3.9A)	0.54A	6dj2B-4njvA: 20.0	6dj2B-4njvA: 85.00
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4oqj	PKS (Streptomyces albus)	PF00109 (ketoacyl-synt) PF02801 (Ketoacyl-synt_C) PF16197 (KAsynt_C_assoc)	5	GLY A 672 ALA A 671 GLY A 666 ILE A 665 VAL A 545	None	0.86A	6dj2B-4oqjA: undetectable	6dj2B-4oqjA: 8.33
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4pcg	VP1 (Human polyomavirus 6)	PF00718 (Polyoma_coat)	6	ALA A 194 ASP A 144 VAL A 182 GLY A 147 ILE A 148 PRO A 188	None	1.42A	6dj2B-4pcgA: undetectable	6dj2B-4pcgA: 17.89
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4pcg	VP1 (Human polyomavirus 6)	PF00718 (Polyoma_coat)	6	ALA A 194 ASP A 195 ASP A 144 VAL A 182 GLY A 147 PRO A 188	None	1.30A	6dj2B-4pcgA: undetectable	6dj2B-4pcgA: 17.89
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4pch	VP1 (Human polyomavirus 7)	PF00718 (Polyoma_coat)	6	ALA A 191 ASP A 144 VAL A 179 GLY A 147 ILE A 148 PRO A 185	None	1.41A	6dj2B-4pchA: undetectable	6dj2B-4pchA: 16.05
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4pch	VP1 (Human polyomavirus 7)	PF00718 (Polyoma_coat)	6	ALA A 191 ASP A 192 ASP A 144 VAL A 179 GLY A 147 PRO A 185	None	1.30A	6dj2B-4pchA: undetectable	6dj2B-4pchA: 16.05
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4phq	HEMOLYSIN E, CHROMOSOMAL (Escherichia coli)	PF06109 (HlyE)	5	GLY A 22 ALA A 23 ILE A 247 ILE A 253 VAL A 119	None	0.93A	6dj2B-4phqA: undetectable	6dj2B-4phqA: 11.30
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4q0g	PROBABLE ACETYL-/PROPIONYL-CO A CARBOXYLASE (BETA SUBUNIT) ACCD1 (Mycobacterium tuberculosis)	PF01039 (Carboxyl_trans)	5	ASP A 290 VAL A 287 GLY A 409 ILE A 370 VAL A 297	None	0.89A	6dj2B-4q0gA: undetectable	6dj2B-4q0gA: 13.48
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4tqk	LECTIN 2 (Agrocybe aegerita)	PF13517 (VCBS)	5	ASP A 345 GLY A 350 ASP A 290 VAL A 343 GLY A 371	None	0.92A	6dj2B-4tqkA: undetectable	6dj2B-4tqkA: 11.08
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4us4	TRANSPORTER (Bacillus halodurans)	PF00209 (SNF)	5	GLY A 396 ALA A 93 VAL A 78 PRO A 332 VAL A 331	None	0.95A	6dj2B-4us4A: undetectable	6dj2B-4us4A: 10.40
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4xvo	L,D-TRANSPEPTIDASE (Mycolicibacterium smegmatis)	PF03734 (YkuD)	5	ASP A 107 ALA A 91 ASP A 88 ILE A 84 PRO A 63	None	0.96A	6dj2B-4xvoA: undetectable	6dj2B-4xvoA: 16.98
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4ydf	HTLV-1 PROTEASE (Primate T-lymphotropic virus 1)	PF00077 (RVP)	7	ARG A 10 ASP A 32 GLY A 34 ALA A 35 ASP A 36 VAL A 39 GLY A 58	None 4B1 A 201 (-2.9A) 4B1 A 201 ( 4.6A) 4B1 A 201 (-3.6A) 4B1 A 201 (-4.4A) None 4B1 A 201 (-3.4A)	0.65A	6dj2B-4ydfA: 12.4	6dj2B-4ydfA: 26.72
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4ywk	CELL DIVISION CONTROL PROTEIN 21 (Pyrococcus furiosus)	PF14551 (MCM_N) PF17207 (MCM_OB)	6	GLY A 225 VAL A 221 ILE A 187 GLY A 205 ILE A 206 VAL A 214	None	1.14A	6dj2B-4ywkA: undetectable	6dj2B-4ywkA: 17.82
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4ywl	CELL DIVISION CONTROL PROTEIN 21 (Pyrococcus furiosus)	PF14551 (MCM_N) PF17207 (MCM_OB)	5	ARG A 94 VAL A 221 ILE A 187 GLY A 205 ILE A 206	None	0.93A	6dj2B-4ywlA: undetectable	6dj2B-4ywlA: 17.47
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4ywl	CELL DIVISION CONTROL PROTEIN 21 (Pyrococcus furiosus)	PF14551 (MCM_N) PF17207 (MCM_OB)	5	GLY A 225 VAL A 221 ILE A 187 GLY A 205 ILE A 206	None	0.74A	6dj2B-4ywlA: undetectable	6dj2B-4ywlA: 17.47
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4ywl	CELL DIVISION CONTROL PROTEIN 21 (Pyrococcus furiosus)	PF14551 (MCM_N) PF17207 (MCM_OB)	5	VAL A 221 ILE A 187 GLY A 205 ILE A 206 VAL A 214	None	0.89A	6dj2B-4ywlA: undetectable	6dj2B-4ywlA: 17.47
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5b18	PROTEASE (Human immunodeficiency virus 1)	PF00077 (RVP)	6	ARG A 8 GLY A 27 ALA A 28 ASP A 29 ASP A 30 PRO A 81	None	0.63A	6dj2B-5b18A: 18.0	6dj2B-5b18A: 72.50
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5gw5	T-COMPLEX PROTEIN 1 SUBUNIT EPSILON (Saccharomyces cerevisiae)	PF00118 (Cpn60_TCP1)	5	GLY e 317 ALA e 318 ASP e 319 GLY e 375 VAL e 363	None	0.97A	6dj2B-5gw5e: undetectable	6dj2B-5gw5e: 11.34
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5h6s	AMIDASE (Microbacterium sp. HM58-2)	PF01425 (Amidase)	6	GLY A 124 ALA A 123 ASP A 81 ILE A 79 GLY A 173 VAL A 163	None	1.48A	6dj2B-5h6sA: undetectable	6dj2B-5h6sA: 9.48
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5h9d	FARNESYL PYROPHOSPHATE SYNTHETASE (Staphylococcus aureus)	PF00348 (polyprenyl_synt)	5	ASP A 209 ASP A 210 ILE A 165 GLY A 202 ILE A 201	None	0.94A	6dj2B-5h9dA: undetectable	6dj2B-5h9dA: 14.86
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5inf	CARBOXYL TRANSFERASE (Streptomyces ambofaciens)	PF01039 (Carboxyl_trans)	5	GLY A 431 ALA A 432 ASP A 433 ILE A 410 ILE A 361	None	0.88A	6dj2B-5infA: undetectable	6dj2B-5infA: 13.85
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5n4l	CERULOPLASMIN (Rattus norvegicus)	no annotation	5	ALA A 102 VAL A 88 ILE A 78 GLY A 175 ILE A 174	None	0.85A	6dj2B-5n4lA: undetectable	6dj2B-5n4lA: 19.77
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5ovl	3-OXOACYL-[ACYL-CARR IER-PROTEIN] REDUCTASE FABG (Mycolicibacterium smegmatis)	no annotation	5	GLY A 123 ALA A 124 ILE A 146 GLY A 98 ILE A 99	None None NAP A1001 (-4.6A) NAP A1001 (-3.4A) NAP A1001 (-4.5A)	0.96A	6dj2B-5ovlA: undetectable	6dj2B-5ovlA: 19.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5t2z	PROTEASE (Human immunodeficiency virus 1)	PF00077 (RVP)	9	ARG A 8 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 VAL A 32 ILE A 50 PRO A 81	None	0.53A	6dj2B-5t2zA: 20.0	6dj2B-5t2zA: 78.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5t2z	PROTEASE (Human immunodeficiency virus 1)	PF00077 (RVP)	10	ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 VAL A 32 ILE A 47 GLY A 49 ILE A 50 PRO A 81	None	0.54A	6dj2B-5t2zA: 20.0	6dj2B-5t2zA: 78.75
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5uak	CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (Homo sapiens)	PF00005 (ABC_tran) PF00664 (ABC_membrane) PF14396 (CFTR_R)	5	GLY A1123 ILE A 105 GLY A1130 ILE A1131 VAL A1114	None	0.90A	6dj2B-5uakA: undetectable	6dj2B-5uakA: 3.52
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5ufm	METHYLTRANSFERASE DOMAIN PROTEIN (Burkholderia thailandensis)	no annotation	5	ASP A 95 GLY A 76 ASP A 72 VAL A 120 GLY A 136	SAH A 301 (-2.7A) SAH A 301 (-3.6A) None SAH A 301 (-4.1A) AZ8 A 302 ( 3.5A)	0.90A	6dj2B-5ufmA: undetectable	6dj2B-5ufmA: 17.98
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5x88	CUTINASE (Malbranchea cinnamomea)	no annotation	6	GLY A 114 ALA A 115 VAL A 136 ILE A 151 GLY A 120 ILE A 87	None	1.30A	6dj2B-5x88A: undetectable	6dj2B-5x88A: 21.11
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	6fiv	RETROPEPSIN (Feline immunodeficiency virus)	PF00077 (RVP)	6	ARG A 13 ASP A 30 GLY A 32 ALA A 33 ASP A 34 GLY A 58	None 3TL A 201 (-3.5A) 3TL A 201 (-3.4A) 3TL A 201 (-4.0A) 3TL A 201 (-3.9A) 3TL A 201 (-3.4A)	0.56A	6dj2B-6fivA: 15.6	6dj2B-6fivA: 30.91
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	6fiv	RETROPEPSIN (Feline immunodeficiency virus)	PF00077 (RVP)	6	ARG A 13 ASP A 30 GLY A 32 ALA A 33 ASP A 34 VAL A 99	None 3TL A 201 (-3.5A) 3TL A 201 (-3.4A) 3TL A 201 (-4.0A) 3TL A 201 (-3.9A) None	0.68A	6dj2B-6fivA: 15.6	6dj2B-6fivA: 30.91
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	6upj	HIV-2 PROTEASE (Human immunodeficiency virus 2)	PF00077 (RVP)	8	ARG A 8 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 ILE A 50 PRO A 81	None NIU A 100 (-2.8A) NIU A 100 (-4.5A) NIU A 100 (-3.6A) None None NIU A 100 (-3.9A) None	0.82A	6dj2B-6upjA: 17.8	6dj2B-6upjA: 47.50
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	6upj	HIV-2 PROTEASE (Human immunodeficiency virus 2)	PF00077 (RVP)	6	ASP A 25 ALA A 28 ASP A 30 GLY A 49 ILE A 50 PRO A 81	NIU A 100 (-2.8A) NIU A 100 (-3.6A) None NIU A 100 ( 3.8A) NIU A 100 (-3.9A) None	1.48A	6dj2B-6upjA: 17.8	6dj2B-6upjA: 47.50
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	6upj	HIV-2 PROTEASE (Human immunodeficiency virus 2)	PF00077 (RVP)	8	ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 GLY A 49 ILE A 50 PRO A 81	NIU A 100 (-2.8A) NIU A 100 (-4.5A) NIU A 100 (-3.6A) None None NIU A 100 ( 3.8A) NIU A 100 (-3.9A) None	0.81A	6dj2B-6upjA: 17.8	6dj2B-6upjA: 47.50

[["6DJ2_B_AB1B201_1","1bou","Sphingomonas paucimobilis","4,5-DIOXYGENASE BETA CHAIN","PF02900(LigB)",5,"GLY B 274;ALA B 275;ILE B   8;GLY B 189;VAL B 131","None","0.85A","6dj2B-1bouB:undetectable","6dj2B-1bouB:14.43"],["6DJ2_B_AB1B201_1","1fob","Aspergillus aculeatus","BETA-1,4-GALACTANASE","PF07745(Glyco_hydro_53)",6,"GLY A  40;ALA A  39;ASP A  38;VAL A 324;ILE A  35;ILE A  44","None","1.16A","6dj2B-1fobA:undetectable","6dj2B-1fobA:11.87"],["6DJ2_B_AB1B201_1","1hvc","Human immunodeficiency virus 1","HIV-1 PROTEASE","PF00077(RVP)",8,"ARG A   8;ASP A  25;GLY A  27;ALA A  28;ASP A  30;ILE A  47;ILE A  50;PRO A  81","A79 A 800 (-3.4A);A79 A 800 (-2.7A);A79 A 800 (-3.0A);A79 A 800 (-3.1A);A79 A 800 ( 4.9A);A79 A 800 ( 3.2A);A79 A 800 (-3.8A);A79 A 800 ( 3.9A)","0.80A","6dj2B-1hvcA:13.7","6dj2B-1hvcA:41.30"],["6DJ2_B_AB1B201_1","1hvc","Human immunodeficiency virus 1","HIV-1 PROTEASE","PF00077(RVP)",7,"ARG A   8;ASP A  25;GLY A  27;ALA A  28;ASP A  30;PRO A  81;VAL A  82","A79 A 800 (-3.6A);A79 A 800 (-2.8A);A79 A 800 (-3.0A);A79 A 800 (-3.2A);A79 A 800 ( 4.7A);A79 A 800 ( 3.4A);A79 A 800 (-4.5A)","0.60A","6dj2B-1hvcA:13.7","6dj2B-1hvcA:41.30"],["6DJ2_B_AB1B201_1","1hvc","Human immunodeficiency virus 1","HIV-1 PROTEASE","PF00077(RVP)",10,"ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;VAL A  32;ILE A  47;GLY A  49;ILE A  50;PRO A  81","A79 A 800 (-2.8A);A79 A 800 (-3.0A);A79 A 800 (-3.2A);A79 A 800 (-2.7A);A79 A 800 ( 4.7A);A79 A 800 ( 4.3A);A79 A 800 ( 3.4A);A79 A 800 (-3.4A);A79 A 800 ( 4.0A);A79 A 800 ( 3.4A)","0.57A","6dj2B-1hvcA:13.7","6dj2B-1hvcA:41.30"],["6DJ2_B_AB1B201_1","1hvc","Human immunodeficiency virus 1","HIV-1 PROTEASE","PF00077(RVP)",11,"ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;VAL A  32;ILE A  47;GLY A  49;ILE A  50;PRO A  81;VAL A  82","A79 A 800 (-2.7A);A79 A 800 (-3.0A);A79 A 800 (-3.1A);A79 A 800 (-2.8A);A79 A 800 ( 4.9A);A79 A 800 ( 4.4A);A79 A 800 ( 3.2A);A79 A 800 ( 3.7A);A79 A 800 (-3.8A);A79 A 800 ( 3.9A);A79 A 800 (-4.5A)","0.72A","6dj2B-1hvcA:13.7","6dj2B-1hvcA:41.30"],["6DJ2_B_AB1B201_1","1hvc","Human immunodeficiency virus 1","HIV-1 PROTEASE","PF00077(RVP)",10,"ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;VAL A  32;ILE A  47;GLY A  49;PRO A  81;VAL A  82","A79 A 800 (-2.8A);A79 A 800 (-3.0A);A79 A 800 (-3.2A);A79 A 800 (-2.7A);A79 A 800 ( 4.7A);A79 A 800 ( 4.3A);A79 A 800 ( 3.4A);A79 A 800 (-3.4A);A79 A 800 ( 3.4A);A79 A 800 (-4.5A)","0.61A","6dj2B-1hvcA:13.7","6dj2B-1hvcA:41.30"],["6DJ2_B_AB1B201_1","1p2f","Thermotoga maritima","RESPONSE REGULATOR","PF00072(Response_reg);PF00486(Trans_reg_C)",5,"GLY A  93;ALA A  94;ASP A  95;ILE A  75;ILE A  61","None","0.82A","6dj2B-1p2fA:undetectable","6dj2B-1p2fA:17.13"],["6DJ2_B_AB1B201_1","1q8y","Saccharomyces cerevisiae","SR PROTEIN KINASE","PF00069(Pkinase)",5,"ARG A 287;ASP A 282;GLY A 698;ALA A 697;GLY A 726","None","0.89A","6dj2B-1q8yA:undetectable","6dj2B-1q8yA:12.76"],["6DJ2_B_AB1B201_1","1q9p","Homo sapiens","HIV-1 PROTEASE","PF00077(RVP)",6,"ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;VAL A  32","None","0.41A","6dj2B-1q9pA:10.1","6dj2B-1q9pA:98.75"],["6DJ2_B_AB1B201_1","1q9p","Homo sapiens","HIV-1 PROTEASE","PF00077(RVP)",6,"ASP A  25;GLY A  27;ALA A  28;ASP A  30;VAL A  32;PRO A  81","None","0.79A","6dj2B-1q9pA:10.1","6dj2B-1q9pA:98.75"],["6DJ2_B_AB1B201_1","1siv","Simian immunodeficiency virus","SIV PROTEASE","PF00077(RVP)",9,"ARG A   8;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;GLY A  49;ILE A  50;PRO A  81","None","0.63A","6dj2B-1sivA:18.8","6dj2B-1sivA:49.40"],["6DJ2_B_AB1B201_1","1vrg","Thermotoga maritima","PROPIONYL-COA CARBOXYLASE, BETA SUBUNIT","PF01039(Carboxyl_trans)",6,"GLY A 416;ALA A 417;ASP A 418;ILE A 395;ILE A 346;VAL A 360","None","1.10A","6dj2B-1vrgA:undetectable","6dj2B-1vrgA:11.16"],["6DJ2_B_AB1B201_1","1x0u","Sulfurisphaera tokodaii","HYPOTHETICAL METHYLMALONYL-COA DECARBOXYLASE ALPHA SUBUNIT","PF01039(Carboxyl_trans)",6,"GLY A 424;ALA A 425;ASP A 426;ILE A 403;ILE A 354;VAL A 368","None","1.16A","6dj2B-1x0uA:undetectable","6dj2B-1x0uA:15.08"],["6DJ2_B_AB1B201_1","1yr2","Novosphingobium capsulatum","PROLYL OLIGOPEPTIDASE","PF00326(Peptidase_S9);PF02897(Peptidase_S9_N)",6,"GLY A 539;ALA A 538;ASP A 537;GLY A 529;PRO A 475;VAL A 474","None","1.08A","6dj2B-1yr2A:undetectable","6dj2B-1yr2A:7.62"],["6DJ2_B_AB1B201_1","1yw6","Escherichia coli","SUCCINYLGLUTAMATE DESUCCINYLASE","PF04952(AstE_AspA)",5,"ARG A 250;GLY A 180;ALA A 179;GLY A 242;ILE A 243","None","0.93A","6dj2B-1yw6A:undetectable","6dj2B-1yw6A:15.44"],["6DJ2_B_AB1B201_1","2bkl","Myxococcus xanthus","PROLYL ENDOPEPTIDASE","PF00326(Peptidase_S9);PF02897(Peptidase_S9_N)",6,"GLY A 497;ALA A 496;ASP A 495;GLY A 487;PRO A 431;VAL A 430","None","1.09A","6dj2B-2bklA:undetectable","6dj2B-2bklA:10.16"],["6DJ2_B_AB1B201_1","2eja","Aquifex aeolicus","UROPORPHYRINOGEN DECARBOXYLASE","PF01208(URO-D)",5,"GLY A 192;ALA A 193;ASP A 194;ILE A 134;ILE A 120","None","0.77A","6dj2B-2ejaA:undetectable","6dj2B-2ejaA:10.68"],["6DJ2_B_AB1B201_1","2fmb","Equine infectious anemia virus","EQUINE INFECTIOUS ANEMIA VIRUS PROTEASE","PF00077(RVP)",8,"ARG A   8;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ILE A  53;PRO A  86;VAL A  87","LP1 A 201 (-3.5A);LP1 A 201 (-2.3A);LP1 A 201 (-3.8A);LP1 A 201 (-3.5A);LP1 A 201 (-3.6A);LP1 A 201 (-4.6A);LP1 A 201 (-3.9A);LP1 A 201 ( 4.9A)","0.64A","6dj2B-2fmbA:15.0","6dj2B-2fmbA:28.85"],["6DJ2_B_AB1B201_1","2fmb","Equine infectious anemia virus","EQUINE INFECTIOUS ANEMIA VIRUS PROTEASE","PF00077(RVP)",8,"ASP A  25;GLY A  27;ALA A  28;ASP A  29;VAL A  32;ILE A  53;GLY A  55;PRO A  86","LP1 A 201 (-2.3A);LP1 A 201 (-3.8A);LP1 A 201 (-3.5A);LP1 A 201 (-3.6A);None;LP1 A 201 (-4.6A);LP1 A 201 (-3.4A);LP1 A 201 (-3.9A)","0.57A","6dj2B-2fmbA:15.0","6dj2B-2fmbA:28.85"],["6DJ2_B_AB1B201_1","2fmb","Equine infectious anemia virus","EQUINE INFECTIOUS ANEMIA VIRUS PROTEASE","PF00077(RVP)",8,"ASP A  25;GLY A  27;ALA A  28;ASP A  29;VAL A  32;ILE A  53;PRO A  86;VAL A  87","LP1 A 201 (-2.3A);LP1 A 201 (-3.8A);LP1 A 201 (-3.5A);LP1 A 201 (-3.6A);None;LP1 A 201 (-4.6A);LP1 A 201 (-3.9A);LP1 A 201 ( 4.9A)","0.58A","6dj2B-2fmbA:15.0","6dj2B-2fmbA:28.85"],["6DJ2_B_AB1B201_1","2fmb","Equine infectious anemia virus","EQUINE INFECTIOUS ANEMIA VIRUS PROTEASE","PF00077(RVP)",5,"GLY A  27;ALA A  28;ASP A  29;VAL A  32;GLY A  54","LP1 A 201 (-3.8A);LP1 A 201 (-3.5A);LP1 A 201 (-3.6A);None;LP1 A 201 (-3.6A)","0.93A","6dj2B-2fmbA:15.0","6dj2B-2fmbA:28.85"],["6DJ2_B_AB1B201_1","2fym","Escherichia coli","ENOLASE","PF00113(Enolase_C);PF03952(Enolase_N)",6,"GLY A 174;ALA A 175;VAL A 178;ILE A 182;GLY A 185;ILE A 170","None","1.46A","6dj2B-2fymA:undetectable","6dj2B-2fymA:11.37"],["6DJ2_B_AB1B201_1","2isq","Arabidopsis thaliana","CYSTEINE SYNTHASE","PF00291(PALP)",5,"GLY A 190;ALA A 189;GLY A 183;ILE A 180;PRO A 296","None;None;PLP A 400 (-3.4A);PLP A 400 (-4.9A);PLP A 400 (-4.0A)","0.79A","6dj2B-2isqA:undetectable","6dj2B-2isqA:14.24"],["6DJ2_B_AB1B201_1","2og2","Arabidopsis thaliana","PUTATIVE SIGNAL RECOGNITION PARTICLE RECEPTOR","PF00448(SRP54);PF02881(SRP54_N)",5,"GLY A 288;ASP A  70;VAL A 294;GLY A 255;VAL A 302","None","0.97A","6dj2B-2og2A:undetectable","6dj2B-2og2A:16.01"],["6DJ2_B_AB1B201_1","2qjg","Methanocaldococcus jannaschii","PUTATIVE ALDOLASE MJ0400","PF01791(DeoC)",5,"GLY A 179;ALA A 180;ASP A 181;ILE A 149;VAL A 120","None","0.91A","6dj2B-2qjgA:undetectable","6dj2B-2qjgA:15.87"],["6DJ2_B_AB1B201_1","2qma","Vibrio parahaemolyticus","DIAMINOBUTYRATE-PYRUVATE TRANSAMINASE AND L-2,4-DIAMINOBUTYRATE DECARBOXYLASE","PF00282(Pyridoxal_deC)",5,"GLY A 728;ALA A 727;ASP A 755;VAL A 774;ILE A 780","None","0.91A","6dj2B-2qmaA:undetectable","6dj2B-2qmaA:10.54"],["6DJ2_B_AB1B201_1","2rkf","Human immunodeficiency virus 1","PROTEASE RETROPEPSIN","PF00077(RVP)",9,"ARG A   8;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;GLY A  49;ILE A  50;PRO A  81","AB1 A 501 ( 4.7A);AB1 A 501 (-2.4A);AB1 A 501 (-3.9A);AB1 A 501 (-3.5A);AB1 A 501 ( 3.3A);AB1 A 501 (-3.8A);AB1 A 501 (-3.5A);AB1 A 501 (-3.8A);AB1 A 501 (-4.2A)","0.47A","6dj2B-2rkfA:20.4","6dj2B-2rkfA:80.00"],["6DJ2_B_AB1B201_1","2rsp","Rous sarcoma virus","RSV PROTEASE","PF00077(RVP)",5,"ARG A  10;ASP A  37;GLY A  39;ALA A  40;ASP A  41","None","0.76A","6dj2B-2rspA:12.7","6dj2B-2rspA:30.08"],["6DJ2_B_AB1B201_1","2wk1","Actinoalloteichus cyanogriseus","NOVP","PF05711(TylF)",5,"GLY A  28;ALA A  27;ILE A  66;GLY A  99;ILE A 102","None;None;SAH A 301 (-4.1A);None;None","0.95A","6dj2B-2wk1A:undetectable","6dj2B-2wk1A:14.81"],["6DJ2_B_AB1B201_1","3afo","Saccharomyces cerevisiae","NADH KINASE POS5","PF01513(NAD_kinase)",5,"ALA A  48;ASP A  49;ILE A  62;ILE A 195;VAL A 383","None","0.95A","6dj2B-3afoA:undetectable","6dj2B-3afoA:11.91"],["6DJ2_B_AB1B201_1","3c24","Jannaschia sp. CCS1","PUTATIVE OXIDOREDUCTASE","PF03807(F420_oxidored);PF16896(PGDH_C)",5,"GLY A 164;ALA A 165;ILE A 149;GLY A 120;ILE A 119","None","0.89A","6dj2B-3c24A:undetectable","6dj2B-3c24A:14.72"],["6DJ2_B_AB1B201_1","3gt7","Syntrophus aciditrophicus","SENSOR PROTEIN","PF00072(Response_reg)",6,"ARG A 102;GLY A 107;ALA A 108;ASP A 109;ILE A  59;VAL A  63","None","1.27A","6dj2B-3gt7A:undetectable","6dj2B-3gt7A:21.05"],["6DJ2_B_AB1B201_1","3i5g","Doryteuthis pealeii","MYOSIN HEAVY CHAIN ISOFORM A","PF00063(Myosin_head);PF00612(IQ);PF02736(Myosin_N)",5,"GLY A 264;ALA A 265;ASP A 266;GLY A 460;ILE A 459","None","0.88A","6dj2B-3i5gA:undetectable","6dj2B-3i5gA:6.84"],["6DJ2_B_AB1B201_1","3igs","Salmonella enterica","N-ACETYLMANNOSAMINE-6-PHOSPHATE 2-EPIMERASE 2","PF04131(NanE)",5,"GLY A 146;ALA A 147;ASP A 148;VAL A 104;ILE A 122","None","0.85A","6dj2B-3igsA:undetectable","6dj2B-3igsA:16.40"],["6DJ2_B_AB1B201_1","3ipw","Entamoeba histolytica","HYDROLASE TATD FAMILY PROTEIN","PF01026(TatD_DNase)",5,"GLY A 112;ASP A  55;GLY A   9;ILE A   8;VAL A  75","None","0.80A","6dj2B-3ipwA:undetectable","6dj2B-3ipwA:14.75"],["6DJ2_B_AB1B201_1","3kci","Homo sapiens","PROBABLE E3 UBIQUITIN-PROTEIN LIGASE HERC2","PF00415(RCC1)",5,"GLY A4099;ALA A4098;VAL A4042;ILE A3991;GLY A3993","None","0.82A","6dj2B-3kciA:undetectable","6dj2B-3kciA:12.07"],["6DJ2_B_AB1B201_1","3kf3","Schwanniomyces occidentalis","INVERTASE","PF00251(Glyco_hydro_32N);PF08244(Glyco_hydro_32C)",5,"ASP A 287;GLY A 289;ASP A 291;ILE A 485;PRO A 355","None;None;None;None;NAG A5001 ( 4.9A)","0.93A","6dj2B-3kf3A:undetectable","6dj2B-3kf3A:10.79"],["6DJ2_B_AB1B201_1","3mws","Human immunodeficiency virus 1","HIV-1 PROTEASE","PF00077(RVP)",6,"ALA A  28;ASP A  29;ASP A  30;VAL A  32;GLY A  48;PRO A  81","None","1.11A","6dj2B-3mwsA:19.4","6dj2B-3mwsA:75.00"],["6DJ2_B_AB1B201_1","3mws","Human immunodeficiency virus 1","HIV-1 PROTEASE","PF00077(RVP)",12,"ARG A   8;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;VAL A  32;ILE A  47;GLY A  49;ILE A  50;PRO A  81;VAL A  82","None","0.57A","6dj2B-3mwsA:19.4","6dj2B-3mwsA:75.00"],["6DJ2_B_AB1B201_1","3n0l","Campylobacter jejuni","SERINE HYDROXYMETHYLTRANSFERASE","PF00464(SHMT)",5,"GLY A 206;ALA A 205;ILE A 199;PRO A 360;VAL A 284","None","0.95A","6dj2B-3n0lA:undetectable","6dj2B-3n0lA:12.96"],["6DJ2_B_AB1B201_1","3njx","Aspergillus aculeatus","RHAMNOGALACTURONASE B","PF09284(RhgB_N);PF14683(CBM-like);PF14686(fn3_3)",5,"GLY A 346;ASP A 349;VAL A 336;GLY A 420;ILE A 419","None; CA A 800 (-2.9A);None;None;None","0.97A","6dj2B-3njxA:undetectable","6dj2B-3njxA:10.92"],["6DJ2_B_AB1B201_1","3nns","Thermotoga maritima","DNA BINDING RESPONSE REGULATOR B","PF00072(Response_reg)",5,"GLY A  93;ALA A  94;ASP A  95;ILE A  75;ILE A  61","None","0.84A","6dj2B-3nnsA:undetectable","6dj2B-3nnsA:23.36"],["6DJ2_B_AB1B201_1","3o8l","Oryctolagus cuniculus","6-PHOSPHOFRUCTOKINASE, MUSCLE TYPE","PF00365(PFK)",6,"GLY A 224;ALA A 225;ASP A 226;ILE A 260;ILE A 192;VAL A 207","PO4 A 767 ( 4.6A);None;None;None;None;None","1.21A","6dj2B-3o8lA:undetectable","6dj2B-3o8lA:8.52"],["6DJ2_B_AB1B201_1","3o8o","Saccharomyces cerevisiae","6-PHOSPHOFRUCTOKINASE SUBUNIT ALPHA","PF00365(PFK)",6,"GLY A 414;ALA A 415;ASP A 416;ILE A 451;ILE A 382;VAL A 397","None","1.29A","6dj2B-3o8oA:undetectable","6dj2B-3o8oA:8.03"],["6DJ2_B_AB1B201_1","3pqs","Actinobacillus pleuropneumoniae","TRANSFERRIN-BINDING PROTEIN","PF01298(TbpB_B_D);PF17483(TbpB_C);PF17484(TbpB_A)",6,"GLY A 463;ALA A 454;ASP A 455;VAL A 429;ILE A 456;GLY A 460","None","1.11A","6dj2B-3pqsA:undetectable","6dj2B-3pqsA:10.34"],["6DJ2_B_AB1B201_1","3slz","Murine leukemia virus","GAG-PRO-POL POLYPROTEIN","PF00077(RVP)",5,"ASP A  32;GLY A  34;ALA A  35;VAL A  39;GLY A  56","3TL A 126 (-2.4A);3TL A 126 (-3.1A);3TL A 126 ( 4.0A);None;3TL A 126 (-3.4A)","0.55A","6dj2B-3slzA:11.1","6dj2B-3slzA:24.00"],["6DJ2_B_AB1B201_1","3slz","Murine leukemia virus","GAG-PRO-POL POLYPROTEIN","PF00077(RVP)",5,"ASP A  32;GLY A  34;ALA A  35;VAL A  39;PRO A  89","3TL A 126 (-2.4A);3TL A 126 (-3.1A);3TL A 126 ( 4.0A);None;3TL A 126 (-4.0A)","0.73A","6dj2B-3slzA:11.1","6dj2B-3slzA:24.00"],["6DJ2_B_AB1B201_1","3t3c","Human immunodeficiency virus 1","HIV-1 PROTEASE","PF00077(RVP)",7,"ARG A   8;GLY A  27;ASP A  29;VAL A  32;ILE A  47;GLY A  49;ILE A  50","SO4 A 101 (-3.8A);017 A 201 (-3.4A);017 A 201 (-3.5A);None;None;017 A 201 (-4.0A);017 A 201 (-3.3A)","0.93A","6dj2B-3t3cA:18.0","6dj2B-3t3cA:75.00"],["6DJ2_B_AB1B201_1","3t3c","Human immunodeficiency virus 1","HIV-1 PROTEASE","PF00077(RVP)",10,"ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;VAL A  32;ILE A  47;GLY A  49;ILE A  50;PRO A  81","017 A 201 (-2.6A);017 A 201 (-3.4A);017 A 201 (-3.5A);017 A 201 (-3.5A);017 A 201 (-4.2A);None;None;017 A 201 (-4.0A);017 A 201 (-3.3A);None","0.96A","6dj2B-3t3cA:18.0","6dj2B-3t3cA:75.00"],["6DJ2_B_AB1B201_1","3t44","Mycobacterium tuberculosis","INDOLE-3-GLYCEROL PHOSPHATE SYNTHASE","PF00218(IGPS)",5,"GLY A 235;ALA A 236;ASP A 237;ILE A 217;ILE A 206","None","0.71A","6dj2B-3t44A:undetectable","6dj2B-3t44A:15.12"],["6DJ2_B_AB1B201_1","3ttp","Human immunodeficiency virus 1","HIV-1 PROTEASE","PF00077(RVP)",9,"ARG A   8;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;GLY A  49;ILE A  50;PRO A  81","017 A 201 ( 4.8A);017 A 201 (-2.6A);017 A 201 (-3.6A);017 A 201 (-3.4A);017 A 201 (-3.3A);017 A 201 (-4.6A);017 A 201 (-3.0A);017 A 201 (-3.3A);017 A 201 (-4.1A)","0.44A","6dj2B-3ttpA:19.3","6dj2B-3ttpA:75.00"],["6DJ2_B_AB1B201_1","3u7s","Human immunodeficiency virus 1","POL POLYPROTEIN","PF00077(RVP)",6,"ARG A   8;ASP A  25;ALA A  28;ASP A  30;GLY A  49;ILE A  50","None;017 A 202 ( 2.5A);017 A 201 (-3.4A);017 A 201 ( 4.0A);017 A 202 (-2.9A);017 A 201 ( 3.5A)","1.43A","6dj2B-3u7sA:19.6","6dj2B-3u7sA:76.25"],["6DJ2_B_AB1B201_1","3u7s","Human immunodeficiency virus 1","POL POLYPROTEIN","PF00077(RVP)",10,"ARG A   8;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;ILE A  47;GLY A  49;ILE A  50;PRO A  81","None;017 A 202 ( 2.5A);017 A 201 ( 3.5A);017 A 201 (-3.4A);017 A 201 (-3.2A);017 A 201 ( 4.0A);017 A 202 (-3.6A);017 A 202 (-2.9A);017 A 201 ( 3.5A);017 A 202 (-4.0A)","0.70A","6dj2B-3u7sA:19.6","6dj2B-3u7sA:76.25"],["6DJ2_B_AB1B201_1","3uhl","Human immunodeficiency virus 1","PROTEASE","PF00077(RVP)",6,"ASP A  25;GLY A  27;ALA A  28;ASP A  29;PRO A  81;VAL A  82","None","0.65A","6dj2B-3uhlA:15.8","6dj2B-3uhlA:80.00"],["6DJ2_B_AB1B201_1","4b2o","Bacillus subtilis","YMDB PHOSPHODIESTERASE","PF13277(YmdB)",5,"GLY A  59;ALA A  60;ASP A  61;ILE A  35;VAL A   9","None","0.76A","6dj2B-4b2oA:undetectable","6dj2B-4b2oA:14.63"],["6DJ2_B_AB1B201_1","4dzh","Xanthomonas campestris","AMIDOHYDROLASE","PF01979(Amidohydro_1)",5,"ALA A 355;ILE A  25;GLY A 370;ILE A 369;VAL A 381","None","0.92A","6dj2B-4dzhA:undetectable","6dj2B-4dzhA:10.78"],["6DJ2_B_AB1B201_1","4ezd","Bos taurus","UREA TRANSPORTER 1","PF03253(UT)",5,"GLY A 333;VAL A  64;ILE A 228;GLY A 230;ILE A 130","SEY A 401 (-3.6A);None;None;SEY A 401 ( 4.0A);None","0.95A","6dj2B-4ezdA:undetectable","6dj2B-4ezdA:12.26"],["6DJ2_B_AB1B201_1","4ict","Mycobacterium tuberculosis","CYTOCHROME P450 121","PF00067(p450)",5,"ARG A 184;GLY A 191;ALA A 190;ASP A 220;GLY A 227","None","0.77A","6dj2B-4ictA:undetectable","6dj2B-4ictA:10.96"],["6DJ2_B_AB1B201_1","4ilk","Escherichia coli","STARVATION SENSING PROTEIN RSPB","PF00107(ADH_zinc_N);PF08240(ADH_N)",5,"GLY A 206;ALA A 207;ASP A 208;ILE A 190;ILE A 176","None","0.78A","6dj2B-4ilkA:undetectable","6dj2B-4ilkA:11.44"],["6DJ2_B_AB1B201_1","4j5u","Rickettsia rickettsii","SERINE HYDROXYMETHYLTRANSFERASE","PF00464(SHMT)",5,"ALA A 173;ASP A 201;VAL A 224;ILE A 202;PRO A 219","None;LLP A 230 ( 2.9A);None;None;None","0.92A","6dj2B-4j5uA:undetectable","6dj2B-4j5uA:11.81"],["6DJ2_B_AB1B201_1","4jga","Rickettsia rickettsii","3-OXOACYL-[ACYL-CARRIER-PROTEIN] SYNTHASE 2","PF00109(ketoacyl-synt);PF02801(Ketoacyl-synt_C)",5,"GLY A 276;ALA A 301;ASP A 304;ILE A 273;ILE A 184","None","0.94A","6dj2B-4jgaA:undetectable","6dj2B-4jgaA:10.09"],["6DJ2_B_AB1B201_1","4kpu","Acidaminococcus fermentans","ELECTRON TRANSFER FLAVOPROTEIN ALPHA\/BETA-SUBUNIT","PF01012(ETF)",5,"GLY B  77;ALA B  78;ASP B  79;VAL B   5;ILE B   3","None","0.95A","6dj2B-4kpuB:undetectable","6dj2B-4kpuB:16.03"],["6DJ2_B_AB1B201_1","4m0d","Haemophilus influenzae","N-ACETYLMURAMIC ACID 6-PHOSPHATE ETHERASE","PF01380(SIS)",6,"GLY A 107;ALA A 106;ASP A 129;VAL A 153;ILE A  74;GLY A  80","None","1.38A","6dj2B-4m0dA:undetectable","6dj2B-4m0dA:19.70"],["6DJ2_B_AB1B201_1","4m98","Neisseria gonorrhoeae","PILIN GLYCOSYLATION PROTEIN","PF00132(Hexapep)",5,"GLY A 302;VAL A 295;ILE A 289;ILE A 324;VAL A 331","None","0.96A","6dj2B-4m98A:undetectable","6dj2B-4m98A:19.43"],["6DJ2_B_AB1B201_1","4njv","Human immunodeficiency virus 1","PROTEASE","PF00077(RVP)",5,"ALA A  28;ASP A  29;ASP A  30;VAL A  32;GLY A  48","RIT A 500 (-3.6A);RIT A 500 (-3.2A);RIT A 500 (-4.8A);None;RIT A 500 (-4.8A)","0.83A","6dj2B-4njvA:20.0","6dj2B-4njvA:85.00"],["6DJ2_B_AB1B201_1","4njv","Human immunodeficiency virus 1","PROTEASE","PF00077(RVP)",10,"ARG A   8;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;VAL A  32;GLY A  49;ILE A  50;PRO A  81","RIT A 500 (-3.2A);RIT A 500 (-2.4A);RIT A 500 (-3.9A);RIT A 500 (-3.6A);RIT A 500 (-3.2A);RIT A 500 (-4.8A);None;RIT A 500 (-3.4A);RIT A 500 (-4.3A);RIT A 500 (-3.9A)","0.57A","6dj2B-4njvA:20.0","6dj2B-4njvA:85.00"],["6DJ2_B_AB1B201_1","4njv","Human immunodeficiency virus 1","PROTEASE","PF00077(RVP)",10,"ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;VAL A  32;ILE A  47;GLY A  49;ILE A  50;PRO A  81","RIT A 500 (-2.4A);RIT A 500 (-3.9A);RIT A 500 (-3.6A);RIT A 500 (-3.2A);RIT A 500 (-4.8A);None;RIT A 500 ( 4.5A);RIT A 500 (-3.4A);RIT A 500 (-4.3A);RIT A 500 (-3.9A)","0.54A","6dj2B-4njvA:20.0","6dj2B-4njvA:85.00"],["6DJ2_B_AB1B201_1","4oqj","Streptomyces albus","PKS","PF00109(ketoacyl-synt);PF02801(Ketoacyl-synt_C);PF16197(KAsynt_C_assoc)",5,"GLY A 672;ALA A 671;GLY A 666;ILE A 665;VAL A 545","None","0.86A","6dj2B-4oqjA:undetectable","6dj2B-4oqjA:8.33"],["6DJ2_B_AB1B201_1","4pcg","Human polyomavirus 6","VP1","PF00718(Polyoma_coat)",6,"ALA A 194;ASP A 144;VAL A 182;GLY A 147;ILE A 148;PRO A 188","None","1.42A","6dj2B-4pcgA:undetectable","6dj2B-4pcgA:17.89"],["6DJ2_B_AB1B201_1","4pcg","Human polyomavirus 6","VP1","PF00718(Polyoma_coat)",6,"ALA A 194;ASP A 195;ASP A 144;VAL A 182;GLY A 147;PRO A 188","None","1.30A","6dj2B-4pcgA:undetectable","6dj2B-4pcgA:17.89"],["6DJ2_B_AB1B201_1","4pch","Human polyomavirus 7","VP1","PF00718(Polyoma_coat)",6,"ALA A 191;ASP A 144;VAL A 179;GLY A 147;ILE A 148;PRO A 185","None","1.41A","6dj2B-4pchA:undetectable","6dj2B-4pchA:16.05"],["6DJ2_B_AB1B201_1","4pch","Human polyomavirus 7","VP1","PF00718(Polyoma_coat)",6,"ALA A 191;ASP A 192;ASP A 144;VAL A 179;GLY A 147;PRO A 185","None","1.30A","6dj2B-4pchA:undetectable","6dj2B-4pchA:16.05"],["6DJ2_B_AB1B201_1","4phq","Escherichia coli","HEMOLYSIN E, CHROMOSOMAL","PF06109(HlyE)",5,"GLY A  22;ALA A  23;ILE A 247;ILE A 253;VAL A 119","None","0.93A","6dj2B-4phqA:undetectable","6dj2B-4phqA:11.30"],["6DJ2_B_AB1B201_1","4q0g","Mycobacterium tuberculosis","PROBABLE ACETYL-\/PROPIONYL-COA CARBOXYLASE (BETA SUBUNIT) ACCD1","PF01039(Carboxyl_trans)",5,"ASP A 290;VAL A 287;GLY A 409;ILE A 370;VAL A 297","None","0.89A","6dj2B-4q0gA:undetectable","6dj2B-4q0gA:13.48"],["6DJ2_B_AB1B201_1","4tqk","Agrocybe aegerita","LECTIN 2","PF13517(VCBS)",5,"ASP A 345;GLY A 350;ASP A 290;VAL A 343;GLY A 371","None","0.92A","6dj2B-4tqkA:undetectable","6dj2B-4tqkA:11.08"],["6DJ2_B_AB1B201_1","4us4","Bacillus halodurans","TRANSPORTER","PF00209(SNF)",5,"GLY A 396;ALA A  93;VAL A  78;PRO A 332;VAL A 331","None","0.95A","6dj2B-4us4A:undetectable","6dj2B-4us4A:10.40"],["6DJ2_B_AB1B201_1","4xvo","Mycolicibacterium smegmatis","L,D-TRANSPEPTIDASE","PF03734(YkuD)",5,"ASP A 107;ALA A  91;ASP A  88;ILE A  84;PRO A  63","None","0.96A","6dj2B-4xvoA:undetectable","6dj2B-4xvoA:16.98"],["6DJ2_B_AB1B201_1","4ydf","Primate T-lymphotropic virus 1","HTLV-1 PROTEASE","PF00077(RVP)",7,"ARG A  10;ASP A  32;GLY A  34;ALA A  35;ASP A  36;VAL A  39;GLY A  58","None;4B1 A 201 (-2.9A);4B1 A 201 ( 4.6A);4B1 A 201 (-3.6A);4B1 A 201 (-4.4A);None;4B1 A 201 (-3.4A)","0.65A","6dj2B-4ydfA:12.4","6dj2B-4ydfA:26.72"],["6DJ2_B_AB1B201_1","4ywk","Pyrococcus furiosus","CELL DIVISION CONTROL PROTEIN 21","PF14551(MCM_N);PF17207(MCM_OB)",6,"GLY A 225;VAL A 221;ILE A 187;GLY A 205;ILE A 206;VAL A 214","None","1.14A","6dj2B-4ywkA:undetectable","6dj2B-4ywkA:17.82"],["6DJ2_B_AB1B201_1","4ywl","Pyrococcus furiosus","CELL DIVISION CONTROL PROTEIN 21","PF14551(MCM_N);PF17207(MCM_OB)",5,"ARG A  94;VAL A 221;ILE A 187;GLY A 205;ILE A 206","None","0.93A","6dj2B-4ywlA:undetectable","6dj2B-4ywlA:17.47"],["6DJ2_B_AB1B201_1","4ywl","Pyrococcus furiosus","CELL DIVISION CONTROL PROTEIN 21","PF14551(MCM_N);PF17207(MCM_OB)",5,"GLY A 225;VAL A 221;ILE A 187;GLY A 205;ILE A 206","None","0.74A","6dj2B-4ywlA:undetectable","6dj2B-4ywlA:17.47"],["6DJ2_B_AB1B201_1","4ywl","Pyrococcus furiosus","CELL DIVISION CONTROL PROTEIN 21","PF14551(MCM_N);PF17207(MCM_OB)",5,"VAL A 221;ILE A 187;GLY A 205;ILE A 206;VAL A 214","None","0.89A","6dj2B-4ywlA:undetectable","6dj2B-4ywlA:17.47"],["6DJ2_B_AB1B201_1","5b18","Human immunodeficiency virus 1","PROTEASE","PF00077(RVP)",6,"ARG A   8;GLY A  27;ALA A  28;ASP A  29;ASP A  30;PRO A  81","None","0.63A","6dj2B-5b18A:18.0","6dj2B-5b18A:72.50"],["6DJ2_B_AB1B201_1","5gw5","Saccharomyces cerevisiae","T-COMPLEX PROTEIN 1 SUBUNIT EPSILON","PF00118(Cpn60_TCP1)",5,"GLY e 317;ALA e 318;ASP e 319;GLY e 375;VAL e 363","None","0.97A","6dj2B-5gw5e:undetectable","6dj2B-5gw5e:11.34"],["6DJ2_B_AB1B201_1","5h6s","Microbacterium sp. HM58-2","AMIDASE","PF01425(Amidase)",6,"GLY A 124;ALA A 123;ASP A  81;ILE A  79;GLY A 173;VAL A 163","None","1.48A","6dj2B-5h6sA:undetectable","6dj2B-5h6sA:9.48"],["6DJ2_B_AB1B201_1","5h9d","Staphylococcus aureus","FARNESYL PYROPHOSPHATE SYNTHETASE","PF00348(polyprenyl_synt)",5,"ASP A 209;ASP A 210;ILE A 165;GLY A 202;ILE A 201","None","0.94A","6dj2B-5h9dA:undetectable","6dj2B-5h9dA:14.86"],["6DJ2_B_AB1B201_1","5inf","Streptomyces ambofaciens","CARBOXYL TRANSFERASE","PF01039(Carboxyl_trans)",5,"GLY A 431;ALA A 432;ASP A 433;ILE A 410;ILE A 361","None","0.88A","6dj2B-5infA:undetectable","6dj2B-5infA:13.85"],["6DJ2_B_AB1B201_1","5n4l","Rattus norvegicus","CERULOPLASMIN","no annotation",5,"ALA A 102;VAL A  88;ILE A  78;GLY A 175;ILE A 174","None","0.85A","6dj2B-5n4lA:undetectable","6dj2B-5n4lA:19.77"],["6DJ2_B_AB1B201_1","5ovl","Mycolicibacterium smegmatis","3-OXOACYL-[ACYL-CARRIER-PROTEIN] REDUCTASE FABG","no annotation",5,"GLY A 123;ALA A 124;ILE A 146;GLY A  98;ILE A  99","None;None;NAP A1001 (-4.6A);NAP A1001 (-3.4A);NAP A1001 (-4.5A)","0.96A","6dj2B-5ovlA:undetectable","6dj2B-5ovlA:19.75"],["6DJ2_B_AB1B201_1","5t2z","Human immunodeficiency virus 1","PROTEASE","PF00077(RVP)",9,"ARG A   8;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;VAL A  32;ILE A  50;PRO A  81","None","0.53A","6dj2B-5t2zA:20.0","6dj2B-5t2zA:78.75"],["6DJ2_B_AB1B201_1","5t2z","Human immunodeficiency virus 1","PROTEASE","PF00077(RVP)",10,"ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;VAL A  32;ILE A  47;GLY A  49;ILE A  50;PRO A  81","None","0.54A","6dj2B-5t2zA:20.0","6dj2B-5t2zA:78.75"],["6DJ2_B_AB1B201_1","5uak","Homo sapiens","CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR","PF00005(ABC_tran);PF00664(ABC_membrane);PF14396(CFTR_R)",5,"GLY A1123;ILE A 105;GLY A1130;ILE A1131;VAL A1114","None","0.90A","6dj2B-5uakA:undetectable","6dj2B-5uakA:3.52"],["6DJ2_B_AB1B201_1","5ufm","Burkholderia thailandensis","METHYLTRANSFERASE DOMAIN PROTEIN","no annotation",5,"ASP A  95;GLY A  76;ASP A  72;VAL A 120;GLY A 136","SAH A 301 (-2.7A);SAH A 301 (-3.6A);None;SAH A 301 (-4.1A);AZ8 A 302 ( 3.5A)","0.90A","6dj2B-5ufmA:undetectable","6dj2B-5ufmA:17.98"],["6DJ2_B_AB1B201_1","5x88","Malbranchea cinnamomea","CUTINASE","no annotation",6,"GLY A 114;ALA A 115;VAL A 136;ILE A 151;GLY A 120;ILE A  87","None","1.30A","6dj2B-5x88A:undetectable","6dj2B-5x88A:21.11"],["6DJ2_B_AB1B201_1","6fiv","Feline immunodeficiency virus","RETROPEPSIN","PF00077(RVP)",6,"ARG A  13;ASP A  30;GLY A  32;ALA A  33;ASP A  34;GLY A  58","None;3TL A 201 (-3.5A);3TL A 201 (-3.4A);3TL A 201 (-4.0A);3TL A 201 (-3.9A);3TL A 201 (-3.4A)","0.56A","6dj2B-6fivA:15.6","6dj2B-6fivA:30.91"],["6DJ2_B_AB1B201_1","6fiv","Feline immunodeficiency virus","RETROPEPSIN","PF00077(RVP)",6,"ARG A  13;ASP A  30;GLY A  32;ALA A  33;ASP A  34;VAL A  99","None;3TL A 201 (-3.5A);3TL A 201 (-3.4A);3TL A 201 (-4.0A);3TL A 201 (-3.9A);None","0.68A","6dj2B-6fivA:15.6","6dj2B-6fivA:30.91"],["6DJ2_B_AB1B201_1","6upj","Human immunodeficiency virus 2","HIV-2 PROTEASE","PF00077(RVP)",8,"ARG A   8;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;ILE A  50;PRO A  81","None;NIU A 100 (-2.8A);NIU A 100 (-4.5A);NIU A 100 (-3.6A);None;None;NIU A 100 (-3.9A);None","0.82A","6dj2B-6upjA:17.8","6dj2B-6upjA:47.50"],["6DJ2_B_AB1B201_1","6upj","Human immunodeficiency virus 2","HIV-2 PROTEASE","PF00077(RVP)",6,"ASP A  25;ALA A  28;ASP A  30;GLY A  49;ILE A  50;PRO A  81","NIU A 100 (-2.8A);NIU A 100 (-3.6A);None;NIU A 100 ( 3.8A);NIU A 100 (-3.9A);None","1.48A","6dj2B-6upjA:17.8","6dj2B-6upjA:47.50"],["6DJ2_B_AB1B201_1","6upj","Human immunodeficiency virus 2","HIV-2 PROTEASE","PF00077(RVP)",8,"ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;GLY A  49;ILE A  50;PRO A  81","NIU A 100 (-2.8A);NIU A 100 (-4.5A);NIU A 100 (-3.6A);None;None;NIU A 100 ( 3.8A);NIU A 100 (-3.9A);None","0.81A","6dj2B-6upjA:17.8","6dj2B-6upjA:47.50"]]